Menu
Search
|

Menu

Close
X

AtriCure Inc ATRC.OQ (NASDAQ Stock Exchange Global Market)

16.93 USD
-0.03 (-0.18%)
As of 1:11 AM IST
chart
Previous Close 16.96
Open 16.90
Volume 24,823
3m Avg Volume 59,455
Today’s High 17.05
Today’s Low 16.81
52 Week High 25.09
52 Week Low 14.89
Shares Outstanding (mil) 34.33
Market Capitalization (mil) 804.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
87
FY16
155
FY15
130
EPS (USD)
FY17
-0.531
FY16
-1.055
FY15
-0.953
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
4.85
5.77
Price to Book (MRQ)
vs sector
4.98
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
24.00
16.52
LT Debt to Equity (MRQ)
vs sector
20.72
12.22
Return on Investment (TTM)
vs sector
-13.17
14.43
Return on Equity (TTM)
vs sector
-19.19
16.13

EXECUTIVE LEADERSHIP

Richard Johnston
Independent Chairman of the Board, Since 2005
Salary: --
Bonus: --
Michael Carrel
President, Chief Executive Officer, Director, Since 2012
Salary: $645,750.00
Bonus: $183,720.00
M. Andrew Wade
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $322,992.00
Bonus: $61,903.00
Douglas Seith
Chief Operating Officer, Since 2015
Salary: $386,100.00
Bonus: $110,996.00
Justin Noznesky
Senior Vice President, Marketing and Business Development, Since 2016
Salary: $294,813.00
Bonus: $56,771.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

7555 Innovation Way
MASON   OH   45040-9695

Phone: +1513.7554100

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

SPONSORED STORIES